ABTCL Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$108,200.00 |
| 52 Week High | US$117,270.00 |
| 52 Week Low | US$81,085.00 |
| Beta | 0.74 |
| 1 Month Change | -0.20% |
| 3 Month Change | 16.37% |
| 1 Year Change | 16.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABTCL | CL Medical Equipment | CL Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 16.4% | 0% | 0% |
Return vs Industry: ABTCL exceeded the CL Medical Equipment industry which returned -3.6% over the past year.
Return vs Market: ABTCL matched the CL Market which returned 16.6% over the past year.
Price Volatility
| ABTCL volatility | |
|---|---|
| ABTCL Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: ABTCL has not had significant price volatility in the past 3 months.
Volatility Over Time: ABTCL's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of CL stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABTCL fundamental statistics | |
|---|---|
| Market cap | CL$176.29t |
| Earnings (TTM) | CL$5.41t |
| Revenue (TTM) | CL$38.92t |
32.6x
P/E Ratio4.5x
P/S RatioIs ABTCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABTCL income statement (TTM) | |
|---|---|
| Revenue | US$40.33b |
| Cost of Revenue | US$18.03b |
| Gross Profit | US$22.29b |
| Other Expenses | US$16.68b |
| Earnings | US$5.61b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.23 |
| Gross Margin | 55.28% |
| Net Profit Margin | 13.91% |
| Debt/Equity Ratio | 40.9% |
How did ABTCL perform over the long term?
See historical performance and comparison